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Abstract 
Background: Titanium dioxide  (TiO2) particles are commonly used as a food additive (E171 in the EU) for its whit‑
ening and opacifying properties. However, the risk of gut barrier disruption is an increasing concern because of the 
presence of a nano‑sized fraction. Food‑grade E171 may interact with mucus, a gut barrier protagonist still poorly 
explored in food nanotoxicology. To test this hypothesis, a comprehensive approach was performed to evaluate 
in vitro and in vivo interactions between  TiO2 and intestinal mucus, by comparing food‑grade E171 with NM‑105 
(Aeroxyde P25) OECD reference nanomaterial.
Results: We tested E171‑trapping properties of mucus in vitro using HT29‑MTX intestinal epithelial cells. Time‑lapse 
confocal laser scanning microscopy was performed without labeling to avoid modification of the particle surface. 
Near‑UV irradiation of E171  TiO2 particles at 364 nm resulted in fluorescence emission in the visible range, with a 
maximum at 510 nm. The penetration of E171  TiO2 into the mucoid area of HT29‑MTX cells was visualized in situ. One 
hour after exposure,  TiO2 particles accumulated inside “patchy” regions 20 µm above the substratum. The structure of 
mucus produced by HT29‑MTX cells was characterized by MUC5AC immunofluorescence staining. The mucus layer 
was thin and organized into regular “islands” located approximately 20 µm above the substratum. The region‑specific 
trapping of food‑grade  TiO2 particles was attributed to this mucus patchy structure. We compared  TiO2‑mediated 
effects in vivo in rats after acute or sub‑chronic oral daily administration of food‑grade E171 and NM‑105 at relevant 
exposure levels for humans. Cecal short‑chain fatty acid profiles and gut mucin O‑glycosylation patterns remained 
unchanged, irrespective of treatment.
Conclusions: Food‑grade  TiO2 is trapped by intestinal mucus in vitro but does not affect mucin O‑glycosylation and 
short‑chain fatty acid synthesis in vivo, suggesting the absence of a mucus barrier impairment under “healthy gut” 
conditions.
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Background
Titanium dioxide  (TiO2) is widely used as a white pig-
ment and opacifying agent, due to its brightness and high 
refractive index. It accounts for 70% of the world’s pig-
ment production, with 5000 metric tons produced per 
year, expected to rise to 60,000 metric tons by 2025. It is 
used in the food industry in an ultrafine form as a white 
coloring agent [referred to as food-grade additive E171 
in the European Union (EU)] for confectionery, sauces, 
cakes, and pastries. In the United States, the Food and 
Drug Administration (FDA) approved the use of food-
grade  TiO2 in 1966 with the stipulation that  TiO2 should 
not exceed 1% by weight of the food [1]. In Europe, EU 
Directive 94/36/EC authorizes the use of E171 in food-
stuffs, without establishment of acceptable daily intake 
by the Joint Food and Agriculture Organization (FAO)/
World Health Organization (WHO) Expert Committee 
on Food Additives, because intestinal  TiO2 absorption 
was considered to be very low [2]. A sizable fraction of 
nano-sized particles (primary particle size < 100  nm) 
is produced during the manufacturing process of the 
powder, accounting for 17–55% of the particles present, 
depending on the commercial supplier of E171 [3–6]. 
Consumption has been estimated to be 1–2  mg  TiO2/
kg body weight (bw)/day for US children under 10 years 
of age, and 0.2–0.7  mg  TiO2/kg bw/day for other US 
consumers [3]. More recent exposure estimates have 
ranged between 0.2 and 0.4 mg/kg bw/day in infants and 
the elderly, and 5.5 and 10.4  mg/kg  bw/day in children, 
depending on the exposure scenario [7].
To date, most data concerning the consequences of 
 TiO2 exposure on intestinal barrier function have been 
obtained in  vitro using enterocyte-like cell models 
[8–15], hence bypassing the mucus layer. However, an 
increasing body of evidence suggests that mucus plays a 
key role in gut barrier homeostasis and host protection 
[16]. Mucus is on the front line, acting in concert with the 
intestinal epithelium and microbiota, to provide physical, 
biological, and chemical barriers to potentially harmful 
food particles [17–20]. However, mucus has only spo-
radically been taken into account when considering the 
fate of nanoparticles in the gut, as recently reviewed [21, 
22]. In particular, there is only limited information con-
cerning  TiO2 and oro-gastrointestinal mucus [6, 23–25], 
even though  TiO2 nanoparticles were first shown to stim-
ulate mucin secretion by human ChaGo-K1 bronchial 
epithelial cells in the airways [26]. Porcine mucosa has 
been used as an ex vivo model for the oral cavity [24, 25], 
whereas Caco-2/HT29-MTX mucus-producing co-cul-
ture has been used to mimic gut-like conditions in vitro 
[6, 23]. Finally, the interactions between  TiO2 nanoparti-
cles and mucus have been primarily characterized using 
standard nano-sized particles  (TiO2-NP) [23–25], despite 
their size (primary size and percentage of nano-sized 
particles) and physico-chemical properties (crystalline 
structure, surface chemical composition, specific sur-
face area, isoelectric point and agglomeration) which are 
quite different from those of food-grade  TiO2 [4, 27]. The 
sole exception has been the recent study of Dorier et al. 
[6] on E171.
We performed a mucus-targeted study using food-
grade  TiO2 (E171) in comparison with the NM-105 
(Aeroxyde P25) OECD (Organisation for Economic 
Cooperation and Development) reference nanomaterial. 
The  TiO2-trapping properties of mucus were evaluated 
for E171 using an in vitro approach with mucus-secret-
ing HT29-MTX intestinal epithelial cells. We also com-
pared the  TiO2-mediated effects in vivo in rats after acute 
(1-week) or sub-chronic (60 days) oral daily administra-
tion of E171 vs. NM-105 at relevant exposure levels for 
humans (0.1 and 10  mg/kg body weight (bw)/day). We 
focused on (i) cecal short-chain fatty acids, which were 
previously shown to be involved in the regulation of 
intestinal mucin MUC2 expression [28], and (ii) mucin 
O-glycosylation, because it influences the cohesive prop-
erties of mucus and hence its protective function [20].
Methods
Particle preparation
The E171 sample, obtained from a French commercial 
supplier of food coloring, was of the same batch as that 
used in the study of Bettini et al. [5]. NM-105 nanomate-
rial (also referenced as JRCNM01005a) was provided by 
the European Union Joint Research Centre (EU JRC) as 
a test material of manufactured  TiO2 nanoparticles (Aer-
oxyde P25) and selected by the OECD for safety evalu-
ation of titanium-based nanomaterials. It displays mixed 
crystallinity, with anatase as the predominant form 
(85% anatase:15% rutile), and a primary particle diam-
eter of 22 ± 1 nm [29]. The  TiO2 products were prepared 
according to the generic Nanogenotox dispersion proto-
col described by Jensen et al. [30]. Briefly, a 2.56 mg/mL 
stock suspension was prepared by pre-wetting the pow-
der in absolute ethanol, followed by dispersion in a 0.05% 
(w/v) bovine serum albumin (BSA) solution and probe 
sonication on ice for 27 min at 40% amplitude (Sonifier 
Cell Disruptor Model 250 20  kHz, Branson Ultrason-
ics Corporation). The stock suspensions were always 
prepared fresh prior to each experiment, sonicated, and 
diluted to the target test concentrations with MilliQ-
grade water.
Particle characterization
The hydrodynamic diameter and polydispersity index 
of the  TiO2 particles after the dispersion protocol were 
measured for E171 and NM-105 at a concentration of 
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40 µg/mL in Milli-Q grade water by Dynamic Light Scat-
tering (DLS, Zetasizer µV, Malvern Instruments Ltd., 
UK). Their global electrical surface properties were also 
assessed by measuring electrophoretic mobility (EM), 
which corresponds to the velocity of suspended particles 
under the influence of an applied electrical field. EM was 
measured in 1  mM  KNO3 with an automated laser zet-
ameter (Zetaphoremetre II, CAD Instruments, France) 
under a 100-V electric field. The pH of the suspension 
was adjusted to between 2 and 7 by adding either nitric 
acid  (HNO3, Sigma-Aldrich) or potassium hydroxide 
(KOH, Sigma-Aldrich). The results are based on an auto-
mated video analysis of approximately 200–300 parti-
cles for each measurement. The mean velocity of the 
E171 and NM-105  TiO2 particles was determined and 
expressed as EM in  10−8 m2/s/V.
Cell culture
The HT29-MTX mucus-secreting subpopulation of the 
human colon carcinoma cell line HT29 [31] was kindly 
provided to the Micalis Institute (MT) by Dr. Thécla 
Lesuffleur (INSERM UMR S 938, Paris, France). Cells 
were routinely grown in Dulbecco’s modified Eagle’s 
minimal essential medium (DMEM) with 4.5 g/L glucose 
(Lonza, Verviers, Belgium), supplemented with 10% (v/v) 
fetal calf serum (FCS) (Lonza) inactivated for 1 h at 56 °C, 
1% (v/v) l-Glutamine 200 mM (Lonza), and 1% (v/v) pen-
icillin 10,000 U/mL-streptomycin 10,000 µg/mL (Lonza). 
Cells were seeded at a concentration of 1.2 × 105 cells/
mL in µ-Slide 8-well glass bottom slides (Ibidi Biovalley, 
Nanterre, France) or on glass coverslips placed in 24-well 
tissue culture plates (Thermo Fisher Scientific—Nunc 
A/S, Waltham, MA USA) for time-lapse microscopy and 
fluorescent staining, respectively. Fully differentiated 
cells were obtained 21 days post-seeding [32]. Cells were 
maintained at 37  °C in a 10%  CO2:90% air atmosphere 
and the culture medium changed daily.
Fluorescent staining of mucus secreted by HT29‑MTX cells
Fluorescent staining was performed as previously 
described [33] with several modifications. HT29-MTX 
cells were fixed with 4% paraformaldehyde (PFA) (Ther-
moFisher Scientific—Fisher Scientific, Waltham, MA 
USA) for 15  min at room temperature, washed three 
times with cold phosphate buffered saline (PBS), pH 
7.5 (Lonza), and blocked for 90 min at room tempera-
ture with 3% (w/v) BSA (Sigma-Aldrich, St. Louis, MO, 
USA) in PBS. Two primary antibodies (Santa Cruz 
Biotechnology, Heidelberg, Germany) were used: rab-
bit anti-MUC5AC (H-160), as MUC5AC is the most 
prominent gel-forming mucin in this in  vitro model 
[31] and mouse anti-E-cadherin (G-10) to visualize epi-
thelial cells (tight junctions). Both were used overnight 
at 4 °C at a 1:200 dilution each. Incubation with the sec-
ondary antibodies was carried out for 1 h at room tem-
perature using 1:400 diluted anti-rabbit Alexa Fluor 647 
and anti-mouse Alexa Fluor 555 goat antibodies (Ther-
moFisher Scientific—Invitrogen, Waltham, MA USA). 
After each incubation with antibody, HT29-MTX cells 
were washed 4 times with cold PBS for 10 min. Stained 
glass coverslips were mounted on Superfrost micro-
scope slides (ThermoFisher Scientific—ThermoScien-
tific, Waltham, MA USA) using ProLong Gold antifade 
reagent (Cat. No. P36930, ThermoFisher Scientific—
Life Technologies, Waltham, MA USA) and examined 
on an Leica TCS SP8 AOBS inverted confocal micro-
scope (Leica Microsystems, Mannheim, Germany) 
equipped with a motorized stage at the INRA MIMA2 
platform (http://www.jouy.inra.fr/mima2 /). Observa-
tions were performed with a 63 ×/1.40 N.A. oil immer-
sion objective. Alexa Fluor 555 was excited at 561  nm 
using an argon laser and detected between 566 and 
628  nm. Alexa Fluor 647 was simultaneously excited 
at 633  nm using a He/Ne laser and the emitted fluo-
rescence recorded from 638 to 794  nm. Signals were 
recorded using hybrid detectors (HyD) in standard 
mode. Single 3D acquisitions were acquired at a scan 
speed of 600 Hz in bidirectional mode with a scanning 
zoom of 1, an image resolution of 1024 × 1024 pixels, 
a line average of 2, and for z-stacks, a z-step between 
each xy image of 0.3  μm. The images were analyzed, 
and graphical representations prepared using IMARIS 
7.7.2 software (Bitplane, Zurich, Switzerland).
Confocal laser scanning microscopy of  TiO2 particles 
in contact with HT29‑MTX cells
Visualization of  TiO2 particle distribution
The distribution of E171 vs. NM-105  TiO2 particles at 
a concentration of 250  µg/mL around HT29-MTX cells 
was observed using a Leica TCS SP5 confocal laser scan-
ning microscope (Leica Microsystems, France) located at 
the Centre de Photonique Biomédicale (CPBM) (Orsay, 
France). The autofluorescence of both cells and particles 
was excited at 364  nm with a continuous Argon laser 
and collected between 400 and 700 nm, using a 63× oil 
immersion objective with a 1.4 numerical aperture. The 
size of the images was 512 × 512 pixels. Z-stacks were 
recorded with a z-step of 1  µm from the substratum 
to the top of the biological structure. To discriminate 
between  TiO2 particles and HT29-MTX cells, spectra 
were reconstructed by imaging the epifluorescence on a 
photomultiplier with a 10-nm slit, which was moved by 
3-nm steps. Spectral deconvolution was performed using 
the “Dye separation” process of the Leica acquisition 
software.
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Visualization of  TiO2 particle penetration as a function 
of time
Diffusive penetration of 250  µg/mL  TiO2 particles 
through the mucoid structure of HT29-MTX cells was 
measured by time-lapse microscopy using the same 
Leica TCS SP5 microscope, as previously described [34]. 
Briefly, the evolution of fluorescence intensity over time 
was observed in a focal plane located 18  µm above the 
glass surface to observe the mucus area. An x–y time 
series was initiated, in which images were collected every 
30 s for 60 min, immediately after  TiO2 aqueous suspen-
sions were very gently and homogeneously added to the 
medium above the cells. Images were analyzed using 
Leica software (Lite; Leica Microsystems, France). Simul-
taneous transmission imaging showed that no structural 
alteration of the cells occurred during this process.
Animals and experimental design
Adult male Wistar rats (175–200 g) were purchased from 
Janvier Labs (France) and housed in polypropylene cages 
under standard conditions (temperature 22 ± 2  °C and a 
12-h light/dark cycle). Animals were allowed free access 
to food (standard pellets HARLAN 2018, Envigo RMS 
SARL, Gannat, France) and water. All experiments were 
approved by the Local Animal Care and Use Committee 
(TOXCOM-0036-EH–EH), in compliance with European 
directive 2010/63/UE. In the first series of experiments, 
rats were randomly divided into three groups, each con-
taining eight animals, and dosed daily by intragastric gav-
age (200  μL) for 7  days with food-grade E171, NM-105 
(10  mg/kg bw/day), or vehicle (water). In the second 
series of experiments, rats were randomly divided into 
three groups, each containing 10 animals, and exposed 
for 60 days to E171 at the same dose as in the previous 
experiment or a lower dose (0.1 mg/kg bw/day), through 
the drinking water, or water alone for the control animals. 
All rats were decapitated and the cecal contents collected 
for analysis of short-chain fatty acids and tissues from the 
small intestine and distal colon were sampled for mucin 
O-glycosylation.
Analysis of cecal short‑chain fatty acids
The concentrations of short-chain fatty acids (SCFA), 
namely acetate, propionate, butyrate, valerate, caproate, 
isobutyrate, isovalerate, and isocaproate, were deter-
mined in the cecal contents by gas–liquid chromatogra-
phy (Nelson 1020, Perkin-Elmer, St Quentin en Yvelines, 
France) as previously described [35]. SCFA concentra-
tions are expressed in mM.
Analysis of gut mucin O‑glycosylation
Jejunal and/or ileal and distal colonic mucosa were 
scraped and the mucins solubilized and purified by 
isopycnic density-gradient centrifugation (Beckman 
Coulter LE80K ultracentrifuge; 70.1 Ti rotor, 308,500×g 
at 15  °C for 72  h) [36]. The mucin-containing fractions 
were pooled, dialyzed into water, lyophilized, and further 
submitted to β-elimination under reductive conditions 
(0.1 M NaOH, 1 M  KBH4 for 24 h at 45 °C). Permethyla-
tion of the mixture of oligosaccharide alditols was car-
ried out using the sodium hydroxide procedure. After 
derivation, the reaction products were dissolved in 
200 μL methanol and further purified on a C18 Sep-Pak 
(Waters, Milford, MA). Permethylated oligosaccharides 
were analyzed by MALDI-TOF Mass Spectrometry (MS) 
in positive ion reflective mode as [M+Na]+. The rela-
tive percentage of each oligosaccharide was determined 
based on the integration of peaks from the MS spectra.
Results
Physicochemical characterization of food‑grade (E171) vs. 
model (NM‑105)  TiO2
The distribution of the hydrodynamic diameter after son-
ication for E171 and NM-105  TiO2 particles suspended in 
Milli-Q grade water was determined by DLS. E171 had 
a mean hydrodynamic diameter of 255  nm and, under 
the same conditions, NM-105 exhibited a mean hydro-
dynamic diameter of 220  nm (Fig.  1A). This indicated 
that, in both cases, some agglomerates and/or aggregates 
remained in the suspension, given the primary  TiO2 par-
ticle size measured by transmission electron microscopy, 
i.e., 22 ± 1  nm (and 100% of particles below 100  nm in 
diameter) for NM-105 [29] and 118 ± 53 nm (and 44.7% 
of particles below 100  nm in diameter) for our E171 
batch [5]. Figure  1B shows the electrophoretic mobility 
measurements recorded for E171 and NM-105 in 1 mM 
 KNO3 at discrete pH values ranging from 2 to 7. Both 
types of  TiO2 exhibited the typical pH-dependence of the 
electrophoretic mobility of metal oxides, and the isoelec-
tric point (IEP) values for E171 and NM-105 were 4.6 and 
5.3, respectively.
Penetration and localization of  TiO2 particles 
within HT29‑MTX cells
In contrast to the NM-105 nanomaterial where no 
fluorescence emission was detected in the condi-
tions under study, food-grade E171, once excited in 
the near-ultraviolet (UV) range at 364  nm, fluoresced 
in the visible range with a maximum at 510  nm in 
the culture medium (Fig.  3i). Based on these intrin-
sic fluorescence properties, we chose E171 for further 
time-lapse experiments to visualize the penetration 
of  TiO2 particles into the mucoid area of HT29-MTX 
cells in  situ. We observed penetration of food-grade 
 TiO2 particles into the mucus and accumulation inside 
“patchy” regions by setting the focal plane 18 µm above 
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the substratum surface: fluorescence intensity inside 
some areas increased continuously over time, dou-
bling within 1  h (area 1), whereas it remained almost 
unchanged in others (area 2) (Fig.  2). Such differences 
in fluorescence intensity likely indicate region-specific 
accumulation of  TiO2 particles. This preferential locali-
zation of  TiO2 particles was confirmed by z-stacks of 
fluorescence intensity images. Indeed, the only observ-
able signal before E171 addition was cellular autofluo-
rescence in the first micrometers (~ 15  µm) above the 
substratum (Additional file 1). In contrast, we observed 
fluorescence deeper, within patches, 1  h after E171 
addition (Fig.  2 and Additional file  2). We recorded 
spectra at different z-positions to further character-
ize this fluorescence pattern (Fig. 3). Near the substra-
tum, the spectrum displayed a maximum at 480  nm, 
similar to that for the cells alone, whereas 20 µm above 
the substratum (i.e., in the region of high fluorescence 
intensity), the spectrum was identical to that obtained 
with food-grade  TiO2 alone in the cell culture medium 
(Fig.  3i). The spectral images recorded in these differ-
ent focal planes were then deconvoluted to separate the 
fluorescence of  TiO2 from that of the cells (Fig.  3b–d, 
f–h). The fluorescence near the substratum mainly 
originated from the cells, whereas in the upper lay-
ers it originated from the  TiO2 particles, which accu-
mulated into “islands”, while the surrounding medium 
contributed very little to global fluorescence (see the 
black background in Fig.  3f ).  TiO2 accumulation was 
also visualized in the transmission images (Fig. 3a, e) as 
black shadows, because light cannot pass through  TiO2 
particles.
We investigated the region-specific accumulation of 
E171  TiO2 particles by characterizing the structure of 
the mucus produced by HT29-MTX cells by MUC5AC 
immunofluorescence staining followed by confocal laser 
scanning microscopy (Fig.  4). We observed a thin layer 
of mucus, with a thickness of less than 5  µm (Fig.  4B). 
Furthermore, this mucus layer did not homogenously 
cover the cells underneath, but was rather organized as 
regular “islands”, located approximately 20 µm above the 
substratum (Fig.  4A, B), consistent with the  TiO2 accu-
mulation pattern depicted above. Thus, the region-spe-
cific trapping of food-grade  TiO2 may be related to the 
patchy structure of the mucus, even though these fluo-
rescence experiments do not provide direct experimental 
evidence.
TiO2 oral exposure in rats: impact on cecal short‑chain fatty 
acids and mucin O‑glycosylation
We next evaluated  TiO2-mediated effects in  vivo 
after oral exposure, depending on  TiO2 type (E171 vs. 
NM-105), treatment duration (1-week vs. sub-chronic 
60  days), and the exposure level (0.1  mg/kg bw/day 
vs. 10  mg/kg bw/day). We focused on the synthesis of 
cecal short-chain fatty acids (SCFA) and gut mucin 
O-glycosylation.
A 7-day oral exposure of rats to  TiO2 had little to no 
impact on overall cecal composition of SCFA relative 
to controls, irrespective of  TiO2 type, E171 or NM-105 
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(Figs.  5a and 6a). There were also no significant differ-
ences relative to controls for acetate, propionate, butyrate 
(Fig. 5b), or other SCFAs (Fig. 6b) following sub-chronic 
oral exposure (60  days) with food-grade  TiO2 in the 
drinking water at doses of either 0.1 or 10 mg/kg bw/day, 
i.e., doses approximating human dietary levels for adults 
and children [3, 7]. In addition, there was no effect rela-
tive to controls on mucin O-glycosylation in the small 
intestine of the rats following 7- or 60-day  TiO2 oral 
exposure, regardless of  TiO2 type (E171 and NM-105) or 
E171 dose tested (Fig. 7a, c). Indeed, there were no sub-
stantial modifications for neutral (the most abundant 
structures), sialylated, or sulfated oligosaccharides. The 
proportion of neutral O-glycans was lower in the colon 
of control animals than in the small intestine, which was 
associated with a higher amount of sialylated and sul-
fated structures (Fig. 7). There were also no  TiO2-induced 
changes in colonic O-glycans after either a 1-week or 
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Fig. 2 a Fluorescence intensity image of HT29‑MTX cells in the presence of food‑grade E171 particles recorded 18 µm above the substratum 1 h 
after particle injection. b Evolution of fluorescence intensity over time inside two distinct areas identified by white rectangles in the previous image. 
c Fluorescence intensity image sequence over time in area 1 from injection of food‑grade E171 to 1 h after. λexc = 364 nm. λem = 400–700 nm
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sub-chronic treatment relative to control conditions 
(Fig. 7b, d).
Discussion
The whitening and opacifying properties of  TiO2 are 
commonly exploited when it is used as the food addi-
tive E171. However, the possibility of gut barrier dis-
ruption and/or an intestinal homeostatic imbalance 
(including microbiota dysbiosis) has been of increasing 
concern, due to the presence of a nano-sized fraction in 
this additive [4, 27]. Indeed, recent studies have reported 
adverse effects of in  vitro exposure of intestinal epithe-
lial cells to E171 [6, 11, 37] some of which possibly pre-
dispose the host to intestinal diseases and colorectal 
cancer, as shown in rodents [5, 38]. Intestinal mucus is 
still an underestimated gut target in food nanotoxicol-
ogy [21, 22] and little data is currently available concern-
ing the effects of  TiO2. Most available data have been 
generated using in  vitro cell models, exclusively study-
ing the effects of  TiO2 nanoparticles  (TiO2-NP) [23, 26]. 
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Various profiles for the absorption and transport of 
 TiO2-NP have been described, depending on whether 
epithelial cells are cultured alone or with goblet cells [23]. 
Intracellular  TiO2-NP accumulation has been mapped 
through Ti-distribution imaging by particle-induced 
X-ray emission. The authors showed that Caco-2 cells 
alone in monoculture displayed low levels of intracellu-
lar Ti accumulation after 24 h of contact. In contrast, the 
Fig. 4 MUC5AC immunofluorescence staining of the HT29‑MTX cell line. Representative confocal laser scanning microscopy z‑stack image of 
MUC5AC (in red) produced by HT29‑MTX cells (E‑cadherin, in green) cultured under standard conditions. A z‑stack section (x, y) at the level of the 
mucus; B z‑stack section (x, y) at the level of HT29‑MTX cells with orthogonal x (y, z) and y (x, z) sections on the right and bottom, respectively. The 
image was prepared using the easy 3D section view of IMARIS software with extended view (signal gathered from a thickness of 5 µm)
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same treatment in the presence of goblet cells (Caco-2/
HT29-MTX mucus-producing co-culture) led to 50-fold 
higher levels of intracellular accumulation [23], suggest-
ing facilitated translocation of  TiO2-NP in the presence 
of mucus. In contrast, another study using the same type 
of  TiO2-NP, but Inductively Coupled Plasma Mass Spec-
trometry (ICP-MS) to measure Ti content, showed that 
Ti accumulation in Caco-2 cells after 6 or 48  h of con-
tact was slightly higher than in Caco-2/HT29-MTX cells; 
however, the differences were not statistically significant. 
The same results were obtained after repeated exposure 
for 21 days [6]. Ex vivo studies on porcine buccal mucosa 
also reported that  TiO2-NP were able to permeate the 
mucus layer and penetrate the underlying tissue, regard-
less of their size and hydrophilicity/hydrophobicity [24, 
25].
Physico-chemical analysis of E171 revealed a hydrody-
namic diameter of 255 nm, which was of the same order 
of magnitude as values obtained for the same commercial 
source [5] and other food-grade  TiO2 samples [4], where 
effects of sonication protocols may influence the size of 
agglomerates [39]. E171 was also found to exhibit the typ-
ical pH-dependence of electrophoretic mobility of metal 
oxides, in contrast to the findings reported by Yang et al. 
[4] who observed little change in electrophoretic mobil-
ity as a function of pH for other food-grade  TiO2 sources. 
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Furthermore, the IEP value for E171 was 4.6. Yang et al. 
[4] found a variety of IEP values (i.e., from < 2.5 to 4.0) for 
five food-grade  TiO2 sources, whereas Dudefoi et al. [27] 
reported a narrow range between 4.0 and 4.2 for food-
grade  TiO2 from other suppliers. These differences are 
probably due to the variable use of anionic phosphate-
containing surfactants, as phosphate adsorbed to  TiO2 
surfaces might decrease the IEP [4, 27]. Our food-grade 
 TiO2 was shown to be devoid of any surface coating with 
phosphate [5].
This is the first study to assess the interaction of food-
grade  TiO2 with mucus by coupling in vitro and in vivo 
approaches. For our in vitro experiments on HT29-MTX 
cells, the chosen concentration was of the same order of 
magnitude as that used in the recent study of Dorier et al. 
[6] who analyzed the interactions of E171 with Caco-2/
HT29-MTX cells, in comparison with Caco-2 cells, dur-
ing acute vs. repeated exposure. The authors reported 
that E171 accumulated more than P25 under both expo-
sure scenarios, due to larger E171 agglomerates, which 
settled more quickly than those of the reference nano-
material, leading to a higher level of cell exposure and 
cell response. They also concluded that E171 can cross 
the mucus layer, which was roughly imaged using Alcian 
Blue staining, since the two cellular models with and 
without mucus accumulated similar amounts of  TiO2. 
Here, fluorescent staining with an anti-MUC5AC anti-
body and confocal microscopy enabled visualization of 
the mucus produced by HT29-MTX cells, as MUC5AC 
was shown to be the major gel-forming mucin in this 
in vitro model [31]. We showed that mucus did not form 
a uniform layer above the cell surface, but rather a patchy 
structure with a thickness of less than 5 µm. Even though 
mucus secreted by HT29-MTX cells has been described 
to form a dense gel layer, in some cases entirely covering 
the cell surface [40–42], our observations are in agree-
ment with previous studies in which mucus patches 
were visualized instead [33, 43–45]. Here, we found that 
food-grade  TiO2 particles formed sparsely distributed 
clusters throughout the sample undoubtedly embedded 
in these mucus “islands”. This confirms the in vitro bar-
rier function of mucus against translocation of particles, 
mainly determined by their size, surface charge and sur-
face hydrophobicity [21]. This is in contrast to the find-
ings of Dorier et  al. [6], but was already highlighted by 
Georgantzopoulou et al. [46] using a Caco-2/HT29-MTX 
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Fig. 7 Effect of  TiO2 exposure in rats on the relative percent of neutral, sialylated, and sulfated mucin O‑glycans after (a, b) a 7‑day treatment (black: 
control; light green: NM‑105 10 mg/kg bw/day; light orange: E171 10 mg/kg bw/day) and (c, d) a 60‑day treatment (black: control; light orange 
hatched: E171 0.1 mg/kg bw/day; light orange: E171 10 mg/kg bw/day) in (a, c) small intestine (a: ileum; c: jejunum) and (b, d) distal colon. The 
results shown are average values and standard deviations for three pools of three to four samples for each condition
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co-culture and silver particles of similar size to the  TiO2 
used in this study (200 nm).
We compared the  TiO2 mucus-related effects in rats 
after acute (1-week) or sub-chronic (60  days) oral daily 
administration of E171 vs. NM-105 at relevant exposure 
levels for humans (0.1 and 10  mg/kg bw/day). In  vivo, 
mucus covers the intestinal epithelium but differently 
along the gastrointestinal tract. In particular, in rodents, 
mucus in the small intestine is single-layered and fills up 
the space between the villi and covers them, but is not 
attached to the epithelium and is penetrable to particles 
with the same size than that of bacteria [47]. In con-
trast, in the colon, a two-layered mucus system organi-
zation is generally described [48, 49]: the inner layer is 
densely packed, firmly attached to the epithelium, and 
devoid of bacteria, while the outer layer is movable, has 
an expanded volume and is heavily colonized by bacte-
ria. However, Kamphuis et al. [50] recently proposed that 
the mucus layer in the distal colon of rodents covers the 
faeces instead of the epithelium. This faecal mucus layer 
confines the microbiota to the faeces and prevents it from 
remaining in empty distal colon. In the proximal colon, 
the mucus does not form a separating layer between bac-
teria and epithelium. These findings offer a new view of 
the mucus structure/function relationship. Besides its 
barrier properties, mucus is increasingly recognized to 
exert other key physiological functions essential for gut 
health. In particular, it provides a habitat for the gut 
microbiota since the wide diversity of mucin-derived car-
bohydrates can be utilized by bacteria as carbon sources 
[51–53] and/or preferential binding sites [54]. It was even 
suggested that such enormous repertoire could be at play 
in the region-specific colonization of bacteria in the gut 
[55]. Mucolytic bacteria, some of them being biomark-
ers in gut health and disease [56, 57], possess a large set 
of enzymes (glycosidases, sulphatases, sialidases…) to 
degrade mucin glycans and to harvest oligosaccharides 
for their own metabolism, thus conferring competitive 
advantage for mucosal surface colonization. Another 
important trait for adaptation of intestinal bacteria to the 
mucosal environment is their mucus-binding capacity, 
driven by specific determinants like pili and/or mucus-
binding proteins in lactobacilli [58, 59].
Due to its trapping properties, mucus may act as a res-
ervoir of  TiO2 particles, leading to areas with a high local 
concentration. Owing to the mucus/microbiota interplay 
in the gut, the gut microbiota may be affected because of 
the reported in vitro bacterial toxicity of nano-sized  TiO2 
[60–62], and also food-grade E171 as recently shown by 
our group [63]. Indeed, there is growing evidence that the 
microbiota is a major player in food toxicology in the gut. 
Commensal bacteria have a capacity to metabolize xeno-
biotics and alter their toxicity to the host, as observed for 
drugs. Xenobiotics may themselves alter bacterial popu-
lations that colonize the gut, leading to dysbiosis and 
associated chronic diseases [64–66]. The consequences 
of oral exposure to  TiO2 and other nanoparticles on the 
intestinal microbiota are largely unknown [21, 22, 67, 
68]. Here, we focused on putative in  vivo  TiO2-induced 
changes to the fermentation products (SCFA) of com-
mensal bacteria, because their effects, especially those of 
butyrate, on mucin synthesis and mucus characteristics 
have been described in vitro, ex vivo, and in vivo [19, 28, 
69–71]. In particular, butyrate, propionate, and acetate, 
have been shown to increase MUC2 mRNA synthesis 
in the LS174T cell line [28]. Butyrate increased MUC2 
mRNA levels at low concentrations (1  mM) but had no 
effect at moderate and high concentrations (5–15 mM). 
Stimulation with low concentrations of butyrate 
(1–2  mM) also increased MUC2 protein synthesis [28]. 
On the other hand, as seen above, mucus is an important 
substrate for the intestinal microbiota, especially SCFA-
producing members [72–74] and considerable changes 
in mucus production would therefore result in altered 
SCFA profiles. In our study, exposure to food-grade 
 TiO2 had little to no impact on the overall cecal compo-
sition of SCFA, including butyrate, irrespective of treat-
ment duration (1-week vs. sub-chronic), suggesting that 
there were no substantial changes in mucus “quantity”. 
We then focused on mucus “quality” by assessing mucin 
O-glycosylation. Neither 1-week or sub-chronic exposure 
to food-grade  TiO2 altered O-glycosylation of mucins 
from the small intestine and colon relative to untreated 
animals, first reinforcing the little impact on the “muco-
philic” population of the gut microbiota. The only pub-
lished study on the consequences of oral nanoparticle 
exposure to mucus deals with silver nanoparticles in rats 
[75]. Silver nanoparticle treatment resulted in a decrease 
in the level of neutral and acidic mucins in goblet cells, an 
increase in sialomucin levels, and a decrease in sulfomu-
cin levels. We previously showed that changes in mucin 
O-glycan composition in rats may influence physico-
chemical interactions and then condensation/bundling 
of mucin fibers, with a direct deleterious impact on the 
morphology and physical properties of the mucus net-
work (i.e., loss in cohesive properties), and hence its pro-
tective barrier function [20]. In our study, the absence 
of mucin O-glycan alterations indicates that the protec-
tive function of mucus against particle uptake probably 
remained intact, even after sub-chronic oral exposure to 
food-grade  TiO2.
Conclusions
This study used a comprehensive approach to evaluate 
interactions between food-grade  TiO2 (E171 additive) 
and intestinal mucus. Results were compared with those 
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of the NM-105 (Aeroxyde P25) OECD reference nano-
material. We showed region-specific trapping of food-
grade  TiO2 particles by mucus-secreting HT29-MTX 
intestinal epithelial cells, likely due to the patchy struc-
ture of mucus in this in  vitro model. Cecal short-chain 
fatty acid profiles and mucin O-glycosylation patterns in 
the small intestine and colon were unchanged for E171 
and also NM-105 after acute (1-week) and sub-chronic 
(60 days) oral exposure of rats at relevant exposure lev-
els for humans (0.1 and 10 mg/kg body weight (bw)/day), 
suggesting the absence of a mucus barrier impairment 
under these “healthy gut” conditions. However, the pro-
tective functions of mucus are not static, as alterations 
in mucus production and composition have been shown 
to occur in response to microbial challenge, variations in 
diet, and intestinal disorders. These factors might influ-
ence the effects of the food additive E171. It should thus 
be informative to evaluate the risks of food-grade  TiO2 
uptake specifically in  situations in which the intestinal 
barrier function is defective, in particular an impaired 
mucus barrier.
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